8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Feb 26, 2026·SEC
BeOne Medicines Ltd.(ONC)Earnings, Financials & Key Ratios
ONC•NASDAQ
$313.32
$33.48B mkt cap·9.5× P/E·Price updated May 6, 2026
AboutBeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.Show more
- Revenue$5.34B+40.2%
- EBITDA$589M+248.5%
- Net Income$287M+144.5%
- EPS (Diluted)32.89+637.4%
- Gross Margin87.49%+3.6%
- EBITDA Margin11.02%+205.9%
- Operating Margin8.37%+156.1%
- Net Margin5.37%+131.7%
- ROE7.46%+139.7%
- ROIC18.64%+167.4%
- Debt/Equity0.46+41.5%
- Interest Coverage8.16
ONC Key Insights
BeOne Medicines Ltd. (ONC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 17.6% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 76.8%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ONC Price & Volume
BeOne Medicines Ltd. (ONC) stock price & volume — 10-year historical chart
Loading chart...
ONC Growth Metrics
BeOne Medicines Ltd. (ONC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years89.78%
5 Years76.85%
3 Years55.69%
TTM37.44%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM230.75%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1349.33%
Return on Capital
10 Years-31.93%
5 Years-17.66%
3 Years-11%
Last Year8.88%
ONC Recent Earnings
BeOne Medicines Ltd. (ONC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (63%)●Beat Revenue 3/12 qtrs (50%)
Q2 2026Latest
May 6, 2026EPS
$26.65
Est $0.81
+3206.5%
Revenue
$1.5B
Est $1.4B
+5.4%
Q1 2026
Feb 26, 2026EPS
$0.58
Est $1.60
-63.7%
Revenue
$1.5B
Est $1.5B
+2.2%
Q4 2025
Nov 6, 2025EPS
$1.09
Est $0.72
+51.4%
Revenue
$1.4B
Est $1.5B
-2.7%
Q3 2025
Aug 6, 2025EPS
$0.84
Est $0.48
+75.0%
Revenue
$1.3B
Est $1.4B
-8.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $26.65vs $0.81+3206.5% | $1.5Bvs $1.4B+5.4% |
| Q1 2026 | Feb 26, 2026 | $0.58vs $1.60-63.7% | $1.5Bvs $1.5B+2.2% |
| Q4 2025 | Nov 6, 2025 | $1.09vs $0.72+51.4% | $1.4Bvs $1.5B-2.7% |
| Q3 2025 | Aug 6, 2025 | $0.84vs $0.48+75.0% | $1.3Bvs $1.4B-8.8% |
Based on last 12 quarters of dataView full earnings history →
ONC Peer Comparison
BeOne Medicines Ltd. (ONC) competitors in Commercial Specialty Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZYME | 2.05B | 27.61 | -25.56 | 38.87% | -76.56% | -26% | 0.07 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 |
Compare ONC vs Peers
BeOne Medicines Ltd. (ONC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ONC Income Statement
BeOne Medicines Ltd. (ONC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 238.39M | 198.22M | 428.21M | 308.87M | 1.18B | 1.42B | 2.46B | 3.81B | 5.34B | 5.74B |
| Revenue Growth % | 22179.16% | -16.85% | 116.03% | -27.87% | 280.83% | 20.37% | 73.65% | 54.96% | 40.23% | 37.44% |
| Cost of Goods Sold | 273.99M | 707.71M | 71.19M | 70.66M | 164.91M | 286.48M | 379.92M | 594.09M | 668.54M | 670.75M |
| COGS % of Revenue | 114.94% | 357.03% | 16.62% | 22.88% | 14.02% | 20.23% | 15.45% | 15.59% | 12.51% | - |
| Gross Profit | -35.6M▲ 0% | -509.49M▼ 1331.0% | 357.02M▲ 170.1% | 238.22M▼ 33.3% | 1.01B▲ 324.6% | 1.13B▲ 11.7% | 2.08B▲ 84.1% | 3.22B▲ 54.7% | 4.67B▲ 45.3% | 5.07B▲ 0% |
| Gross Margin % | -14.94% | -257.03% | 83.38% | 77.12% | 85.98% | 79.77% | 84.55% | 84.41% | 87.49% | 88.31% |
| Gross Profit Growth % | 63.28% | -1330.95% | 170.07% | -33.28% | 324.56% | 11.67% | 84.06% | 54.71% | 45.34% | - |
| Operating Expenses | 62.85M | 196.28M | 1.32B | 1.9B | 2.45B | 2.92B | 3.29B | 3.78B | 4.23B | 4.38B |
| OpEx % of Revenue | 26.37% | 99.02% | 307.54% | 613.81% | 208.29% | 206.16% | 133.67% | 99.32% | 79.12% | - |
| Selling, General & Admin | 62.6M | 195.38M | 388.25M | 600.18M | 990.12M | 1.28B | 1.51B | 1.83B | 2.08B | 2.18B |
| SG&A % of Revenue | 26.26% | 98.57% | 90.67% | 194.31% | 84.17% | 90.3% | 61.33% | 48.06% | 38.96% | - |
| Research & Development | 269.02M | 679M | 927.34M | 1.29B | 1.46B | 1.64B | 1.78B | 1.95B | 2.15B | 2.21B |
| R&D % of Revenue | 112.85% | 342.55% | 216.56% | 419.22% | 124.06% | 115.86% | 72.34% | 51.26% | 40.16% | - |
| Other Operating Expenses | 11.46M | 1.99M | 1.33M | 846K | 750K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -98.46M▲ 0% | -705.77M▼ 616.8% | -959.89M▼ 36.0% | -1.66B▼ 72.7% | -1.44B▲ 13.2% | -1.79B▼ 24.4% | -1.21B▲ 32.5% | -568.2M▲ 53.0% | 447.14M▲ 178.7% | 685.94M▲ 0% |
| Operating Margin % | -41.3% | -356.05% | -224.16% | -536.69% | -122.31% | -126.4% | -49.12% | -14.91% | 8.37% | 11.95% |
| Operating Income Growth % | 15.89% | -616.83% | -36.01% | -72.69% | 13.21% | -24.39% | 32.52% | 52.95% | 178.69% | - |
| EBITDA | -93.7M | -695.38M | -941.27M | -1.63B | -1.39B | -1.72B | -1.12B | -396.44M | 588.82M | 947.6M |
| EBITDA Margin % | -39.31% | -350.81% | -219.81% | -526.39% | -118.36% | -121.71% | -45.55% | -10.4% | 11.02% | 16.51% |
| EBITDA Growth % | 18.63% | -642.14% | -35.36% | -72.73% | 14.37% | -23.78% | 35.01% | 64.61% | 248.53% | 907.87% |
| D&A (Non-Cash Add-back) | 4.76M | 10.39M | 18.62M | 31.79M | 46.46M | 66.28M | 87.67M | 171.76M | 141.69M | 261.67M |
| EBIT | -98.46M | -705.77M | -959.89M | -1.66B | -1.44B | -1.79B | -1.21B | -568.2M | 475.09M | 442.52M |
| Net Interest Income | -4.11M | 13.95M | 9.13M | 2M | 15.76M | 52.48M | 74.01M | 47.84M | 12.27M | 18.8M |
| Interest Income | 0 | 13.95M | 9.13M | 2M | 15.76M | 52.48M | 74.01M | 47.84M | 70.5M | 104.69M |
| Interest Expense | 4.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58.23M | 25.35M |
| Other Income/Expense | 7.39M | 15.94M | 16.3M | 39.49M | 147K | -171.37M | 381.9M | 35.2M | -30.28M | -30.77M |
| Pretax Income | -91.06M▲ 0% | -689.83M▼ 657.5% | -943.59M▼ 36.8% | -1.62B▼ 71.5% | -1.44B▲ 11.1% | -1.96B▼ 36.3% | -825.84M▲ 57.9% | -533M▲ 35.5% | 416.85M▲ 178.2% | 655.17M▲ 0% |
| Pretax Margin % | -38.2% | -348.01% | -220.35% | -523.9% | -122.3% | -138.5% | -33.59% | -13.99% | 7.8% | 11.42% |
| Income Tax | 2.23M | -15.8M | 6.99M | 10.4M | 19.23M | 42.78M | 55.87M | 111.78M | 129.92M | 142.15M |
| Effective Tax Rate % | -2.45% | 2.29% | -0.74% | -0.64% | -1.34% | -2.18% | -6.77% | -20.97% | 31.17% | 21.7% |
| Net Income | -93.11M▲ 0% | -673.77M▼ 623.7% | -948.63M▼ 40.8% | -1.62B▼ 71.3% | -1.46B▲ 10.3% | -2B▼ 37.5% | -881.71M▲ 56.0% | -644.79M▲ 26.9% | 286.93M▲ 144.5% | 513.02M▲ 0% |
| Net Margin % | -39.06% | -339.91% | -221.53% | -526.1% | -123.93% | -141.52% | -35.86% | -16.92% | 5.37% | 8.94% |
| Net Income Growth % | 21.9% | -623.67% | -40.79% | -71.3% | 10.29% | -37.45% | 56% | 26.87% | 144.5% | 230.75% |
| Net Income (Continuing) | -93.3M | -674.03M | -950.58M | -1.63B | -1.46B | -2B | -881.71M | -644.79M | 286.93M | 513.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 14.42M | 14.45M | 16.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.21▲ 0% | -12.09▼ 447.1% | -15.86▼ 31.2% | -19.11▼ 20.5% | -15.21▲ 20.4% | -19.37▼ 27.4% | -8.45▲ 56.4% | -6.12▲ 27.6% | 32.89▲ 637.4% | 4.43▲ 0% |
| EPS Growth % | 43.33% | -447.06% | -31.18% | -20.49% | 20.41% | -27.35% | 56.38% | 27.57% | 637.42% | 1349.33% |
| EPS (Basic) | -2.21 | -12.09 | -15.86 | -19.11 | -15.21 | -19.37 | -8.45 | -6.12 | 34.19 | - |
| Diluted Shares Outstanding | 41.78M | 55.44M | 60.05M | 83.47M | 92.79M | 103.13M | 104.39M | 105.29M | 113.45M | 115.77M |
| Basic Shares Outstanding | 41.78M | 55.44M | 60.05M | 83.47M | 92.79M | 103.13M | 104.39M | 105.29M | 109.06M | 110.96M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ONC Balance Sheet
BeOne Medicines Ltd. (ONC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 913.5M | 1.94B | 1.17B | 4.96B | 7.61B | 5.21B | 4.2B | 3.99B | 6.23B | 6.6B |
| Cash & Short-Term Investments | 837.52M | 1.78B | 982.74M | 4.65B | 6.62B | 4.53B | 3.17B | 2.63B | 4.55B | 4.79B |
| Cash Only | 239.6M | 712.94M | 618.01M | 1.38B | 4.38B | 3.87B | 3.17B | 2.63B | 4.55B | 4.79B |
| Short-Term Investments | 597.91M | 1.07B | 364.73M | 3.27B | 2.24B | 665.25M | 2.6M | 0 | 0 | 0 |
| Accounts Receivable | 29.43M | 49.67M | 70.88M | 60.4M | 500.18M | 198.98M | 395.89M | 709.11M | 865.08M | 938.02M |
| Days Sales Outstanding | 45.06 | 91.46 | 60.42 | 71.38 | 155.2 | 51.29 | 58.77 | 67.93 | 59.1 | 56.39 |
| Inventory | 10.93M | 16.24M | 28.55M | 89.29M | 242.63M | 282.35M | 416.12M | 494.99M | 608.23M | 681.59M |
| Days Inventory Outstanding | 14.56 | 8.38 | 146.39 | 461.27 | 537.02 | 359.74 | 399.78 | 304.11 | 332.07 | 316.21 |
| Other Current Assets | 25.73M | 17.64M | 76.49M | 19.58M | 328K | 196K | 56.25M | 25.19M | 212.75M | 190M |
| Total Non-Current Assets | 132.98M | 305.84M | 439.59M | 640.07M | 921.64M | 1.17B | 1.6B | 1.93B | 1.95B | 1.95B |
| Property, Plant & Equipment | 62.57M | 194.24M | 324.92M | 446.3M | 662.51M | 923.98M | 1.37B | 1.66B | 1.79B | 1.79B |
| Fixed Asset Turnover | 3.81x | 1.02x | 1.32x | 0.69x | 1.78x | 1.53x | 1.79x | 2.30x | 2.99x | 3.23x |
| Goodwill | 109K | 109K | 109K | 109K | 109K | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 19.71M | 52.23M | 5.85M | 53.73M | 103.35M | 94.57M | 108.86M | 129.76M | 62.7M | 61.68M |
| Long-Term Investments | 0 | 0 | 0 | 49.34M | 100.79M | 91.78M | 89.64M | 128.93M | 82.51M | 302.64M |
| Other Non-Current Assets | 42.91M | 29.73M | 108.72M | 24.62M | -55.53M | 61.89M | 31.57M | 13.38M | 19.91M | 197.09M |
| Total Assets | 1.05B▲ 0% | 2.25B▲ 115.0% | 1.61B▼ 28.3% | 5.6B▲ 247.4% | 8.54B▲ 52.4% | 6.38B▼ 25.3% | 5.81B▼ 9.0% | 5.92B▲ 2.0% | 8.19B▲ 38.3% | 8.55B▲ 0% |
| Asset Turnover | 0.23x | 0.09x | 0.27x | 0.06x | 0.14x | 0.22x | 0.42x | 0.64x | 0.65x | 0.75x |
| Asset Growth % | 157.87% | 114.98% | -28.33% | 247.38% | 52.4% | -25.26% | -9% | 1.99% | 38.3% | 125.89% |
| Total Current Liabilities | 149.99M | 246.45M | 310.31M | 1.08B | 1.6B | 1.47B | 1.81B | 2.21B | 1.83B | 1.81B |
| Accounts Payable | 69.78M | 113.28M | 122.49M | 231.96M | 262.4M | 294.78M | 315.11M | 405M | 479.04M | 423.55M |
| Days Payables Outstanding | 92.96 | 58.43 | 628.01 | 1.2K | 580.79 | 375.58 | 302.74 | 248.82 | 261.54 | 224.07 |
| Short-Term Debt | 9.22M | 8.73M | 0 | 335.01M | 427.56M | 328.97M | 688.37M | 851.53M | 134.71M | 136.72M |
| Deferred Revenue (Current) | 12.23M | 18.14M | 0 | 0 | 187.41M | 213.86M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 18.98M | 31.08M | 56.86M | 234.57M | 260.77M | 299.11M | 285.81M | 359.5M | 1.22B | 1.67B |
| Current Ratio | 6.09x | 7.89x | 3.78x | 4.61x | 4.76x | 3.55x | 2.32x | 1.80x | 3.41x | 3.41x |
| Quick Ratio | 6.02x | 7.82x | 3.69x | 4.53x | 4.61x | 3.35x | 2.09x | 1.58x | 3.08x | 3.08x |
| Cash Conversion Cycle | -33.34 | 41.41 | -421.2 | -665.59 | 111.44 | 35.45 | 155.81 | 123.22 | 129.63 | 148.53 |
| Total Non-Current Liabilities | 212.26M | 249.59M | 323.62M | 656.32M | 803.41M | 527.41M | 457.83M | 373.79M | 2.01B | 1.98B |
| Long-Term Debt | 155.49M | 189.67M | 240.69M | 183.64M | 202.11M | 209.15M | 197.62M | 166.48M | 1.81B | 1.01B |
| Capital Lease Obligations | 0 | 0 | 25.83M | 29.42M | 43.04M | 34.52M | 22.25M | 44.28M | 52.94M | 158.27M |
| Deferred Tax Liabilities | 0 | 11.14M | 0 | 10.79M | 14.17M | 16M | 16.49M | 42.01M | 97.21M | 197.17M |
| Other Non-Current Liabilities | 155K | 1.08M | 57.09M | 383.33M | 277.44M | 187.54M | 187.27M | 90.7M | 51.27M | 1.95B |
| Total Liabilities | 362.25M | 496.04M | 633.93M | 1.73B | 2.4B | 2B | 2.27B | 2.59B | 3.83B | 3.79B |
| Total Debt | 164.72M | 198.4M | 277.34M | 561.96M | 694.64M | 596.67M | 930.18M | 1.08B | 2B | 1.15B |
| Net Debt | -74.89M | -514.54M | -340.67M | -819.99M | -3.68B | -3.27B | -2.24B | -1.55B | -2.55B | -3.64B |
| Debt / Equity | 0.24x | 0.11x | 0.28x | 0.15x | 0.11x | 0.14x | 0.26x | 0.32x | 0.46x | 0.46x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 3.40x | 1.21x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -4.33x | -4.33x |
| Interest Coverage | -23.97x | - | - | - | - | - | - | - | 8.16x | 17.46x |
| Total Equity | 698.65M▲ 0% | 1.77B▲ 153.1% | 978.35M▼ 44.7% | 3.87B▲ 295.5% | 6.13B▲ 58.5% | 4.38B▼ 28.5% | 3.54B▼ 19.3% | 3.33B▼ 5.8% | 4.36B▲ 30.9% | 4.76B▲ 0% |
| Equity Growth % | 97.97% | 153.07% | -44.67% | 295.48% | 58.5% | -28.52% | -19.3% | -5.8% | 30.88% | 99.09% |
| Book Value per Share | 16.72 | 31.89 | 16.29 | 46.35 | 66.09 | 42.50 | 33.89 | 31.65 | 38.44 | 41.12 |
| Total Shareholders' Equity | 684.23M | 1.75B | 962.21M | 3.87B | 6.13B | 4.38B | 3.54B | 3.33B | 4.36B | 4.76B |
| Common Stock | 59K | 77K | 79K | 118K | 133K | 135K | 135K | 138K | 144K | 144K |
| Retained Earnings | -330.52M | -1.01B | -1.96B | -3.55B | -5.08B | -7.08B | -7.96B | -8.61B | -8.32B | -8.09B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -480K | 1.53M | -8M | 6.94M | 17.95M | -77.42M | -99.45M | -148.99M | -78.18M | -53.48M |
| Minority Interest | 14.42M | 14.45M | 16.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ONC Cash Flow Statement
BeOne Medicines Ltd. (ONC) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 12.75M | -547.72M | -750.27M | -1.28B | -1.3B | -1.5B | -1.16B | -140.63M | 1.13B | 1.13B |
| Operating CF Margin % | 5.35% | -276.32% | -175.21% | -415.53% | -110.41% | -105.7% | -47.07% | -3.69% | 21.1% | - |
| Operating CF Growth % | 114.25% | -4395.15% | -36.98% | -71.07% | -1.19% | -15.24% | 22.66% | 87.85% | 901.8% | 1301.48% |
| Net Income | -93.3M | -674.03M | -950.58M | -1.6B | -1.41B | -2B | -881.71M | -644.79M | 286.93M | 513.02M |
| Depreciation & Amortization | 4.76M | 10.39M | 18.62M | 31.79M | 46.46M | 66.28M | 87.67M | 171.76M | 141.69M | 324.15M |
| Stock-Based Compensation | 42.86M | 87.13M | 134.15M | 183.48M | 240.71M | 303.16M | 367.62M | 441.62M | 510.86M | 1.17B |
| Deferred Taxes | -5.84M | -21.95M | -9.23M | -27.81M | -41.09M | 2.06M | 689K | 25.98M | 9.47M | 9.47M |
| Other Non-Cash Items | 7.08M | 67.96M | 67.6M | -20.98M | -13.11M | 3.31M | -361.19M | 21.96M | -12.77M | -1.29B |
| Working Capital Changes | 57.2M | -17.21M | -10.83M | 150.58M | -118.34M | 132.39M | -370.54M | -157.17M | 191.4M | 240.9M |
| Change in Receivables | -29.43M | -11.63M | -29.82M | 10.36M | -423.02M | 304.11M | -188.31M | -329.44M | -164.95M | -208.49M |
| Change in Inventory | -10.93M | -5.31M | -12.31M | -58.91M | -153.33M | -56.69M | -140.95M | -91.5M | -93.17M | -169.19M |
| Change in Payables | 55.3M | 23.47M | 2.22M | 95.83M | 20.01M | -4.35M | 21.48M | 121.5M | 79.83M | 40.97M |
| Cash from Investing | -356.32M | -637.61M | 554.16M | -3.17B | 640.66M | 1.08B | 60M | -548.35M | -276.15M | -199.98M |
| Capital Expenditures | -58.73M | -140.84M | -158.61M | -229.03M | -314.85M | -469.1M | -561.9M | -492.66M | -185.84M | -418.77M |
| CapEx % of Revenue | 24.64% | 71.05% | 37.04% | 74.15% | 26.77% | 33.13% | 22.85% | 12.93% | 3.48% | - |
| Acquisitions | 19.92M | 70.55M | 69M | 109.5M | 51.91M | -1.4B | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -329.86M | -108.85M | -69M | -109.5M | -51.91M | 1.4B | -36.44M | -39.34M | -81.93M | 225.35M |
| Cash from Financing | 490.36M | 1.69B | 85.68M | 5.2B | 3.64B | -18.97M | 416.48M | 193.45M | 1.06B | 1.16B |
| Debt Issued (Net) | 132.76M | 33.58M | 34.68M | 289.6M | 101.53M | -65.94M | 360.77M | 145.08M | 889.71M | 100.25M |
| Equity Issued (Net) | 339.12M | 1.63B | 0 | 4.23B | 3.44B | 0 | 0 | 0 | 196.8M | 19.41M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 18.48M | 29.66M | 51M | 681.21M | 92.76M | 46.96M | 55.71M | 48.37M | -27.06M | 1.04B |
| Net Change in Cash | 152.09M▲ 0% | 501.11M▲ 229.5% | -119.94M▼ 123.9% | 769.23M▲ 741.4% | 2.99B▲ 289.1% | -507.85M▼ 117.0% | -689.05M▼ 35.7% | -547.24M▲ 20.6% | 1.97B▲ 460.2% | 2.32B▲ 0% |
| Free Cash Flow | -45.98M▲ 0% | -688.55M▼ 1397.6% | -908.88M▼ 32.0% | -1.51B▼ 66.4% | -1.61B▼ 6.7% | -1.97B▼ 21.8% | -1.75B▲ 10.8% | -669.77M▲ 61.8% | 941.74M▲ 240.6% | 846.06M▲ 0% |
| FCF Margin % | -19.29% | -347.37% | -212.25% | -489.68% | -137.18% | -138.83% | -71.32% | -17.58% | 17.63% | 14.74% |
| FCF Growth % | 59.32% | -1397.64% | -32% | -66.41% | -6.68% | -21.82% | 10.79% | 61.81% | 240.61% | 451.84% |
| FCF per Share | -1.10 | -12.42 | -15.13 | -18.12 | -17.39 | -19.06 | -16.80 | -6.36 | 8.30 | 8.30 |
| FCF Conversion (FCF/Net Income) | -0.14x | 0.81x | 0.79x | 0.79x | 0.89x | 0.75x | 1.31x | 0.22x | 3.93x | 1.65x |
| Interest Paid | 1.26M | 2.21M | 4.32M | 44.13M | 29.97M | 25.17M | 19.75M | 51.17M | 0 | 23.94M |
| Taxes Paid | 29.29M | 12K | 8.98M | 10.6M | 15.7M | 29.5M | 56M | 69.43M | 0 | 67.71M |
ONC Key Ratios
BeOne Medicines Ltd. (ONC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -17.71% | -54.63% | -69.08% | -67.04% | -29.15% | -38.11% | -22.26% | -18.77% | 7.46% | 12.06% |
| Return on Invested Capital (ROIC) | -16.29% | -56.39% | -76.13% | -67.44% | -39.23% | -75.37% | -75.29% | -27.67% | 18.64% | 18.64% |
| Gross Margin | -14.94% | -257.03% | 83.38% | 77.12% | 85.98% | 79.77% | 84.55% | 84.41% | 87.49% | 88.31% |
| Net Margin | -39.06% | -339.91% | -221.53% | -526.1% | -123.93% | -141.52% | -35.86% | -16.92% | 5.37% | 8.94% |
| Debt / Equity | 0.24x | 0.11x | 0.28x | 0.15x | 0.11x | 0.14x | 0.26x | 0.32x | 0.46x | 0.46x |
| Interest Coverage | -23.97x | - | - | - | - | - | - | - | 8.16x | 17.46x |
| FCF Conversion | -0.14x | 0.81x | 0.79x | 0.79x | 0.89x | 0.75x | 1.31x | 0.22x | 3.93x | 1.65x |
| Revenue Growth | 22179.16% | -16.85% | 116.03% | -27.87% | 280.83% | 20.37% | 73.65% | 54.96% | 40.23% | 37.44% |
ONC SEC Filings & Documents
BeOne Medicines Ltd. (ONC) SEC filings — annual & quarterly reports (10-K, 10-Q)
ONC Frequently Asked Questions
BeOne Medicines Ltd. (ONC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BeOne Medicines Ltd. (ONC) reported $5.74B in revenue for fiscal year 2025. This represents a 51382% increase from $11.1M in 2013.
BeOne Medicines Ltd. (ONC) grew revenue by 40.2% over the past year. This is strong growth.
Yes, BeOne Medicines Ltd. (ONC) is profitable, generating $513.0M in net income for fiscal year 2025 (5.4% net margin).
Dividend & Returns
BeOne Medicines Ltd. (ONC) has a return on equity (ROE) of 7.5%. This is below average, suggesting room for improvement.
BeOne Medicines Ltd. (ONC) generated $846.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ONC
BeOne Medicines Ltd. (ONC) financial analysis — history, returns, DCA and operating performance tools
Full ONC Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates